Digitisation | January 10, 2026
Revvity and Lilly partner to accelerate AI drug discovery models
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
Subscribe To Our Newsletter & Stay Updated
